Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | EIF4E | P06730 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057653 | 0.78 | LIMK1 (0.43) | AKR1C3AKR1C2LIMK1SRD5A2CRHR1 | |
| SCHEMBL4050631 | 0.78 | AR (0.47) | AKR1C3AKR1C2LIMK1AKR1C4AKR1C1 | |
| SCHEMBL4059345 | 0.76 | PDE10A (0.41) | AKR1C3AKR1C2LIMK1CRHR1MAP4K1 | |
| SCHEMBL16446879 | 0.75 | CYP11B2 (0.60) | AKR1C3AKR1C2LIMK1AKR1C4AKR1C1 | |
| SCHEMBL8007347 | 0.75 | AKR1C3 (0.47) | AKR1C3AKR1C2LIMK1SRD5A2AKR1C4 | |
| SCHEMBL4050630 | 0.75 | PDCD1 (0.52) | AKR1C3AKR1C2AKR1C4AKR1C1AKR1B10 | |
| SCHEMBL16526159 | 0.74 | CYP11B1 (0.60) | LIMK1CRHR1LIMK2EPHX2CYP11B1 | |
| SCHEMBL16815294 | 0.73 | CYP1A2 (0.47) | AKR1C3AKR1C2LIMK1CRHR1LIMK2 | |
| SCHEMBL1992428 | 0.73 | EPHX2 (0.58) | EPHX2 | |
| SCHEMBL4060457 | 0.72 | PDK2 (0.42) | AKR1C3AKR1C2LIMK1SRD5A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009111501-A1 | DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | MAVS, SARS1, HAVCR2 | AKR1C3 3422/4885AKR1C2 3861/4885LIMK1 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.